Minsalud Will Unilaterally Set Price Of Medicine For Leukemia - Intellectual Property - Mondaq Chile - Mondaq Business Briefing - Books and Journals - VLEX 653436401

Minsalud Will Unilaterally Set Price Of Medicine For Leukemia

Author:Mr Ismael Berguecio
Profession:Clarke, Modet & Co
 
FREE EXCERPT

Novartis says that the decision touches Intellectual Property principles in all sectors of the country.

Everything seemed that the declaration of the Imatinib molecule to treat cancer as a matter of public interest, would be the third case of compulsory license in Latin America, after the governments of Brazil and Ecuador made use of this power in the past .

Remember that in 2007 the Brazilian government granted a compulsory license for the manufacture of antiretroviral efavirenz, whose patent belongs to Merck Sharp & Dohme. Meanwhile, in 2010 the Government of Ecuador issued a compulsory license allowing the import of ritonavir antiretroviral drug manufacturer Cipla Indian pharmaceutical generic drugs whose patent holder is Abbott.

Being a pre Compulsory license in most of the laws providing for caning law requirement, like what has happened in Colombia with the Imatinib molecule to treat cancer, both in the case of Brazil and Ecuador was negotiated previously and unsuccessfully with the holders of the respective patents, to lower prices, arguing facilitate drug access to most of the population, given its high price.

However, in this case, after failed negotiations with the Swiss drugmaker Novartis, the Ministry of Health of Colombia has decided not to grant compulsory license to another (s) manufacturer (s) of the drug or to allow the import of a generic of the same active ingredient of the drug to a foreign laboratory, but has decided to set the sales price of the drug through an administrative act for the National Commission on drug Pricing and devices define unilaterally the...

To continue reading

REQUEST YOUR TRIAL